Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Payoneer Global Inc (PAYO) Price & Performance

Amylx Pharmaceuticals IncTrade
Payoneer Global IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Payoneer Global Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Payoneer Global Inc trades at $7.08 (market cap $2.40B). The key difference: Amylx Pharmaceuticals Inc and Payoneer Global Inc are close in size by market cap. Which is the better fit depends on your goals.

AMLXPAYO
Market Cap
$2.53B$2.40B
Sector
HealthTechnology
52-Week High
$24.19$7.17
52-Week Low
$7.82$4.27
Enterprise Value
$2.28B$2.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

Payoneer Global Inc

Payoneer Global Inc. (PAYO) trades at $7.10, down 0.14% on the day, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.02, missing estimates, but revenue grew 10% year-over-year. Analysts maintain a 60% buy rating with an $8.20 consensus target, while the pending acquisition by Nuvei for $7.40 per share dominates news, prompting legal scrutiny over fairness.

Outlook is clouded by acquisition uncertainty; upside exists if the deal price is raised, but execution risks and margin pressure persist. Investors face near-term volatility from merger developments, with fundamental growth in B2B payments offering long-term potential if the transaction fails.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Payoneer Global Inc

Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.

Read more on PAYO